Abstract:The WHO (2021) Classification classified a group of pediatric-type high-grade gliomas as IDH wildtype, H3 wildtype but as of currently, they are characterized only by negative molecular features of IDH and H3. We recruited 35 cases of pediatric IDH wildtype and H3 wildtype hemispheric glioblastomas. We evaluated them with genome-wide methylation profiling, targeted sequencing, RNAseq, TERT promoter sequencing, and FISH. The median survival of the cohort was 27.6 months. With Capper et al.’s36 methylation groups as a map, the cases were found to be epigenetically heterogeneous and were clustered in proximity or overlay of methylation groups PXA-like (n = 8), LGG-like (n = 10), GBM_MYCN (n = 9), GBM_midline (n = 5), and GBM_RTKIII (n = 3). Histology of the tumors in these groups was not different from regular glioblastomas. Methylation groups were not associated with OS. We were unable to identify groups specifically characterized by EGFR or PDGFRA amplification as proposed by other authors. EGFR, PDGFRA, and MYCN amplifications were not correlated with OS. 4/9 cases of the GBM_MYCN cluster did not show MYCN amplification; the group was also enriched for EGFR amplification (4/9 cases) and the two biomarkers overlapped in two cases. Overall, PDGFRA amplification was found in only four cases and they were not restricted to any groups. Cases in proximity to GBM_midline were all hemispheric and showed loss of H3K27me3 staining. Fusion genes ALK/NTRK/ROS1/MET characteristic of infantile glioblastomas were not identified in 17 cases successfully sequenced. BRAF V600E was only found in the PXA group but CDKN2A deletion could be found in other methylation groups. PXA-like cases did not show PXA histological features similar to findings by other authors. No case showed TERT promoter mutation. Mutations of mismatch repair (MMR) genes were poor prognosticators in single (p ≤ 0.001) but not in multivariate analyses (p = 0.229). MGMT had no survival significance in this cohort. Of the other common biomarkers, only TP53 and ATRX mutations were significant poor prognosticators and only TP53 mutation was significant after multivariate analyses (p = 0.024). We conclude that IDH wildtype, H3 wildtype pediatric hemispheric glioblastomas are molecularly heterogeneous and in routine practice, TP53, ATRX, and MMR status could profitably be screened for risk stratification in laboratories without ready access to methylation profiling.

Classification Based on Mutations of TERT Promoter and IDH Characterizes Subtypes in Grade II/III Gliomas.

TERT Promoter Mutations Contribute to IDH Mutations in Predicting Differential Responses to Adjuvant Therapies in WHO Grade II and III Diffuse Gliomas.

TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma

TERT Promoter Mutated WHO Grades II and III Gliomas Are Located Preferentially in the Frontal Lobe and Avoid the Midline.

TERT Promoter Mutations Contribute to Subset Prognostication of Lower-Grade Gliomas

Prognostic Impact of TERT Promoter Mutations in Adult-Type Diffuse Gliomas Based on WHO2021 Criteria

TERT Mutation Is Accompanied by Neutrophil Infiltration and Contributes to Poor Survival in Isocitrate Dehydrogenase Wild-Type Glioma

Molecular landscape of <scp> <i>IDH</i> </scp> ‐wild type, <scp> p <i>TERT</i> </scp> ‐wild type adult glioblastomas

Molecular landscape of IDH‐wild type, pTERT‐wild type adult glioblastomas

Abstract 2234: Combined analysis of TERT, EGFR and IDH status define distinct prognostic classes of GBM

TERT Gene Mutation in Gliomas Cross‐Linked With (NTRK, PDL1, ALK, IDH, P53, EGFR, HER2): A Integrative Review TERT Gene Mutation in Gliomas

IDH-1R132H Mutation Status in Diffuse Glioma Patients: Implications for Classification.

Combination Genetic Signature Stratifies Lower-Grade Gliomas Better Than Histological Grade

MPTH-24COMBINATION GENETIC SIGNATURE STRATIFIES PROGNOSIS IN LOWER-GRADE GLIOMAS BUT IDH STATUS ALONE DOES NOT SUPERSEDE HISTOLOGIC GRADES

Adult IDH Wild-Type Lower-Grade Gliomas Should Be Further Stratified

Molecular landscape of pediatric type IDH wildtype, H3 wildtype hemispheric glioblastomas

Idh1/Idh2 Mutations Define The Prognosis And Molecular Profiles Of Patients With Gliomas: A Meta-Analysis

Epid-19. Interaction Between Germline And Somatic Genetics To Elucidate Risk Of Adult Diffuse Glioma

Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci

1242 Metabologenomic Characterization Uncovers Heterogeneity Amongst IDH Mutant Gliomas

Immune Heterogeneity of IDH Glioma Subtypes